Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations
Open Access
Abstract
The application of personalized medicine to lung adenocarcinoma has resulted in new therapies based on specific oncogenic drivers that have improved patient outcomes. However, oncogene-defined subsets of patients exhibit a significant heterogeneity of response to these agents. Defining the factors that mediate the varied depth and duration of response are critical to developing new therapeutic strategies. While the examination of patient samples can provide important correlations, definitive mechanistic studies require the use of relevant preclinical models. Based on a large body of data, interactions between cancer cells and the surrounding tumor microenvironment, comprised of inflammatory, immune, and vascular cells, represent a critical determinant of therapeutic response. In this review, we focus on preclinical models that can be used to explore these interactions, identify new therapeutic targets, and test combination therapies. In particular, we will describe the use of implantable orthotopic immunocompetent models employing a panel of murine lung adenocarcinoma cell lines with oncogenic drivers common to human lung adenocarcinoma as a powerful system to develop new treatment approaches.Keywords
Funding Information
- VA Merit (BX004751-05)
This publication has 108 references indexed in Scilit:
- Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapyCancer and Metastasis Reviews, 2025
- Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic developmentCancer Treatment Reviews, 2024
- Lung cancer statistics, 2023Cancer, 2024
- Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancerImmunity, 2023
- Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib responseCancer Letters, 2023
- Generation of genetically engineered mice for lung cancer with mutant EGFRBiochemical and Biophysical Research Communications, 2022
- Immunotherapy in the treatment of non-small cell lung cancerLung Cancer, 2014
- An Orthotopic Model of Lung Cancer to Analyze Primary and Metastatic NSCLC Growth in Integrin α1-Null MiceClinical & Experimental Metastasis, 2005
- NCI-navy medical oncology branch cell line data baseJournal of Cellular Biochemistry, 1996
- Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell cultureCancer Letters, 1980